Targeted therapies in gastric cancer treatment: where we are and where we are going.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 378, doi. 10.1007/s10637-016-0330-2
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2016 AND VI 34 AND IP 3
Results: 15
1
2
RRx-001, A novel dinitroazetidine radiosensitizer.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 371, doi. 10.1007/s10637-016-0326-y
- By:
- Publication type:
- Article
3
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 394, doi. 10.1007/s10637-016-0329-8
- By:
- Publication type:
- Article
4
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 397, doi. 10.1007/s10637-016-0332-0
- By:
- Publication type:
- Article
5
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 355, doi. 10.1007/s10637-016-0335-x
- By:
- Publication type:
- Article
6
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 290, doi. 10.1007/s10637-016-0336-9
- By:
- Publication type:
- Article
7
Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 261, doi. 10.1007/s10637-016-0337-8
- By:
- Publication type:
- Article
8
Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 269, doi. 10.1007/s10637-016-0340-0
- By:
- Publication type:
- Article
9
Microtubule-stabilizing properties of the avocado-derived toxins (+)-( R)-persin and (+)-( R)-tetrahydropersin in cancer cells and activity of related synthetic analogs.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 277, doi. 10.1007/s10637-016-0341-z
- By:
- Publication type:
- Article
10
Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 300, doi. 10.1007/s10637-016-0342-y
- By:
- Publication type:
- Article
11
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 319, doi. 10.1007/s10637-016-0343-x
- By:
- Publication type:
- Article
12
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 338, doi. 10.1007/s10637-016-0346-7
- By:
- Publication type:
- Article
13
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 347, doi. 10.1007/s10637-016-0347-6
- By:
- Publication type:
- Article
14
Effect of regulation reform on clinical trials for registering novel therapeutic agents in Taiwan: a chronological analysis.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 364, doi. 10.1007/s10637-016-0322-2
- By:
- Publication type:
- Article
15
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α integrin inhibitor E7820 in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 3, p. 329, doi. 10.1007/s10637-016-0344-9
- By:
- Publication type:
- Article